

PRESS RELEASE
09 June 2022 08:30:00 CEST

New Finnish study validates Stockholm3 and shows health economic benefits

At the NUF – Nordisk Urologisk Förening – congress in Helsinki tomorrow a new study that validates the use of Stockholm3 in Finland will be presented. The results of the study show that by using Stockholm3 instead of PSA, the number of men undergoing MRI and/or biopsies could be reduced. The study also shows that the medical benefits of replacing PSA with Stockholm3 can be achieved at the same – or potentially reduced cost in Finland.

“Several studies in multiple countries have shown that Stockholm3 reduces unnecessary MRI and biopsy examinations without compromising the detection of clinically significant prostate cancer. The aim of this study was to compare the distribution of test results in a Finnish clinical cohort”, says Henrikki Santti, Head Physician, Urology at Mehiläinen.

This multi-center, observational study included 1,310 men who were scheduled for a PSA test at Mehiläinen’s healthcare facilities in Finland, and who were asked to donate blood and answer clinical questions. The blood from 473 men with PSA \geq 1.5 ng/mL was analyzed with Stockholm3, and the outcome was compared between using PSA and Stockholm3.

The results of the study indicate that by using Stockholm3 instead of PSA, the number of men undergoing MRI or biopsies could be reduced and that the medical benefits by replacing PSA with Stockholm3 can be achieved at the same – or potentially at a reduced cost in Finland.

“The results of the study were comparable with data from studies including more than 75,000 men in Norway and Sweden. This means that Stockholm3 might improve Finnish clinician’s ability to identify patients at risk of having clinically significant prostate cancer”, says Henrikki Santti.

“Mehiläinen’s mission is to provide outstanding healthcare. We are offering Stockholm3 to our patients to fulfill that mission in prostate cancer diagnostics”, says Kristina Hotakainen, Director of Laboratory Services at Mehiläinen.

Abstract presented at the annual NUF congress in Helsinki:
Research confirms - Prostate cancer diagnosis improves with new blood test - avoiding unnecessary tests reduces burden on patient and healthcare.

Mehiläinen Group is a well-known and highly valued private provider of social and healthcare services, offering comprehensive high-quality services in Finland and internationally. 112-year-old Mehiläinen is a rapidly developing and growing leader in the industry. Mehiläinen invests in the possibilities of digitalisation and the effectiveness and quality of care in all its business areas.

Mehiläinen serves more than 2 million customers annually, and services are produced at over 670 locations by more than 29,000 employees and private practitioners. Internationally, Mehiläinen provides healthcare services in Sweden, Germany, and Estonia, as well as digital healthcare software solutions through its subsidiary BeeHealthy.

For additional information, please contact:

David Rosen, CEO
Telephone: +46 10 1823325
Email: david.rosen@a3p.com

About A3P Biomedical

A3P Biomedical's mission is to improve quality of life of men by radically increasing the precision in prostate cancer diagnostics. The company's lead product is **Stockholm3**, a blood test for early detection of aggressive prostate cancer. Stockholm3 has been developed by scientists at Karolinska Institutet and validated in clinical studies including more than 75,000 men. A total of SEK 750 million has been invested in clinical research, product development and market validation activities of Stockholm3. A3P Biomedical is headquartered in Stockholm, Sweden. For more information, please visit www.a3p.com.

About Stockholm3

Stockholm3 is a blood test that combines protein markers, genetic markers, clinical data, and a proprietary algorithm, to predict the risk of aggressive prostate cancer at an early stage. In clinical practice, Stockholm3 finds 100 percent more aggressive prostate cancers and reduces 50 percent of unnecessary biopsies compared to current practice with PSA (1).

Stockholm3 has been evaluated in clinical studies with more than 75,000 men. Data from the latest pivotal study, a randomized study including 12,750 men, was published in The Lancet Oncology in 2021. Multiple studies have been published in high-impact journals, including a previous study with 58,000 men, published in The Lancet Oncology in 2015 (1).

Based on robust peer-reviewed clinical data, leading Nordic healthcare providers such as Capio S:t Görans Hospital in Sweden and Stavanger University Hospital in Norway have replaced PSA with Stockholm3. Patients benefit from a more precise test (increasing sensitivity and specificity) and healthcare providers can reduce the direct costs by 17 to 28 percent (1).

(1) Publications, results and clinical validation.

About prostate cancer

Prostate cancer is the second most common male cancer, and the fifth leading cause of cancer related death in men worldwide. According to WHO, 1.4 million men were diagnosed with prostate cancer and 375,000 deaths were reported in 2020. Incidence of prostate cancer is expected to increase by 70 percent until 2040, driven by an aging population.

Attachments

[New Finnish study validates Stockholm3 and shows health economic benefits](#)